Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors

Journal of Cutaneous Pathology

Volumn 39, Issue 5, 2012, Pages 493-499

  Al Zaid, Tariq ^a   Ditelberg, Jeremy S ^b   Prieto, Victor G ^a   Lev, Dina ^a,c   Luthra, Raja ^a   Davies, Michael A ^a   Diwan, A Hafeez ^d   Wang, Wei Lien ^a   Lazar, Alexander J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CARIS LIFE SCIENCES   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cowden syndrome; immunohistochemistry; PTEN; trichilemmoma

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOPSY; BIOSYNTHESIS; CONGENITAL TUMOR; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HAMARTOMA SYNDROME, MULTIPLE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PTEN PHOSPHOHYDROLASE; SKIN NEOPLASMS;

EID: 84860217787     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2012.01888.x     Document Type: Article

References (48)

1. James W, Berger T, Elston D., Andrews' diseases of the skin: clinical dermatology, 11th ed. Epidermal nevi, neoplasms, and cysts. Philadelphia, PA: Saunders Elsevier, 2011; 663.
2. Starink TM, van der Veen JP, Arwert F, et al., The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986; 29: 222.
3. Pilarski R., Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009; 18: 13.
4. Salem OS, Steck WD., Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. J Am Acad Dermatol 1983; 8: 686.
5. Marsh DJ, Coulon V, Lunetta KL, et al., Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998; 7: 507.
6. Blumenthal GM, Dennis PA., PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008; 16: 1289.
7. Nelen MR, Kremer H, Konings IB, et al., Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999; 7: 267.
8. Eng C., PTEN: one gene, many syndromes. Hum Mutat 2003; 22: 183.
9. Eng C., Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000; 37: 828.
10. Perren A, Weng LP, Boag AH, et al., Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999; 155: 1253.
11. Pallares J, Bussaglia E, Martínez-Guitarte JL, et al., Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005; 18: 719.
12. Li DM, Sun H., TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57: 2124.
13. Myers MP, Pass I, Batty IH, et al., The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci U S A 1998; 95: 13513.
14. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL., The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998; 95: 15587.
15. Furnari FB, Huang HJ, Cavenee WK., The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 1998; 58: 5002.
16. Li DM, Sun H., PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A 1998; 95: 15406.
17. Ramaswamy S, Nakamura N, Vazquez F, et al., Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999; 96: 2110.
18. Li J, Simpson L, Takahashi M, et al., The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 1998; 58: 5667.
19. Weng LP, Smith WM, Brown JL, Eng C., PTEN inhibits insulin-stimulated MEK/ MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet 2001; 10: 605.
20. Weng LP, Brown JL, Eng C., PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 2001; 10: 599.
21. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM., Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280: 1614.
22. Gu J, Tamura M, Pankov R, et al., Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999; 146: 389.
23. Nelen MR, Padberg GW, Peeters EA, et al., Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996; 13: 114.
24. Nelen MR, van Staveren WC, Peeters EA, et al., Germline mutations in the PTEN/ MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997; 6: 1383.
25. Liaw D, Marsh DJ, Li J, et al., Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64.
26. Marsh DJ, Kum JB, Lunetta KL, et al., PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999; 8: 1472.
27. Zhou X, Hampel H, Thiele H, et al., Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001; 358: 210.
28. Zhou XP, Marsh DJ, Morrison CD, et al., Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet 2003; 73: 1191.
29. Butler MG, Dasouki MJ, Zhou XP, et al., Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 2005; 42: 318.
30. Herman GE, Butter E, Enrile B, Pastore M, Prior TW, Sommer A., Increasing knowledge of PTEN germline mutations: two additional patients with autism and macrocephaly. Am J Med Genet A 2007; 143: 589.
31. Maier D, Zhang Z, Taylor E, et al., Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 1998; 16: 3331.
32. Wang SI, Puc J, Li J, et al., Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997; 57: 4183.
33. Tashiro H, Blazes MS, Wu R, et al., Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57: 3935.
34. Pesche S, Latil A, Muzeau F, et al., PTEN/ MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998; 16: 2879.
35. Bonneau D, Longy M., Mutations of the human PTEN gene. Hum Mutat 2000; 16: 109.
36. Gimm O, Chi H, Dahia PL, et al., Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas. J Clin Endocrinol Metab 2001; 86: 1801.
37. Gimm O, Perren A, Weng LP, et al., Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 2000; 156: 1693.
38. Halachmi N, Halachmi S, Evron E, et al., Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 1998; 23: 239.
39. Reifenberger J, Wolter M, Boström J, et al., Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch 2000; 436: 487.
40. Goel V, Lazar AJ, Redston M, Haluska FG., Examination of mutations in BRAF, NRAS and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006; 126: 154.
41. Kubo Y, Urano Y, Hida Y, Arase S., Lack of somatic mutation in the PTEN gene in squamous cell carcinomas of human skin. J Dermatol Sci 1999; 19: 199.
42. Van Gele M, Leonard JH, Van Roy N, Cook AL, De Paepe A, Speleman F., Frequent allelic loss at 10q23 but low incidence of PTEN mutations in Merkel cell carcinoma. Int J Cancer 2001; 92: 409.
43. Tsao H, Zhang X, Benoit E, Haluska FG., Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998; 16: 3397.
44. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J., Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997; 57: 3660.
45. Goel A, Arnold CN, Niedzwiecki D, et al., Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004; 64: 3014.
46. Peirõ G, Adrover E, Guijarro J, et al., Synchronous bilateral breast carcinoma in a patient with Cowden syndrome: a case report with morphologic, immunohistochemical and genetic analysis. Breast J 2010; 16: 77.
47. Scheper MA, Nikitakis NG, Sarlani E, Sauk JJ, Meiller TF., Cowden syndrome: report of a case with immunohistochemical analysis and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 625.
48. Barletta JA, Bellizzi AM, Hornick JL., Immunohistochemical staining of thyroidectomy specimens for PTEN can aid in the identification of patients with Cowden syndrome. Am J Surg Pathol 2011; 35: 1505.